# SRSF2

Source: https://onco.cc/targets/srsf2/  
OnCo record `srsf2` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SRSF2 (Serine/arginine-rich splicing factor 2) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Myelodysplastic syndromes / neoplasms and 3 more.

## Summary

Necessary for the splicing of pre-mRNA. It is required for formation of the earliest ATP-dependent splicing complex and interacts with spliceosomal components bound to both the 5'- and 3'-splice sites during spliceosome assembly. It also is required for ATP-dependent interactions of both U1 and U2 snRNPs with pre-mRNA.

CIViC holds 4 clinical evidence items and 0 assertions across 3 variants, naming CTX-712. Open Targets scores its association with cancer at 0.83 (direct and indirect evidence; datatypes literature 0.97, affected pathway 0.61, genetic association 0.79, somatic mutation 0.90). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Acute Myeloid Leukaemia.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: serine and arginine rich splicing factor 2; Serine/arginine-rich splicing factor 2; SC-35; SC35; PR264; SFRS2A; SFRS2
- Tags: cancer-genes-wave
- Symbol: SRSF2
- Class: oncogene
- Biology: Necessary for the splicing of pre-mRNA. It is required for formation of the earliest ATP-dependent splicing complex and interacts with spliceosomal components bound to both the 5'- and 3'-splice sites during spliceosome assembly. It also is required for ATP-dependent interactions of both U1 and U2 snRNPs with pre-mRNA. Interacts with other spliceosomal components, via the RS domains, to form a bridge between the 5'- and 3'-splice site binding components, U1 snRNP and U2AF. Binds to purine-rich RNA sequences, either 5'-AGSAGAGTA-3' (S=C or G) or 5'-GTTCGAGTA-3'. Can bind to beta-globin mRNA and commit it to the splicing pathway. Location: Nucleus; Nucleus, nucleoplasm; Nucleus speckle (UniProt). Locus 17q25.2 (HGNC).
- Where found: Myeloproliferative neoplasms: Open Targets association 0.83 with myeloproliferative neoplasm (MONDO_0020076); Leukaemia: Open Targets association 0.83 with leukaemia (MONDO_0005059); Myelodysplastic syndromes / neoplasms: Open Targets association 0.68 with myelodysplastic syndrome (MONDO_0018881); CIViC evidence names this disease; Non-Hodgkin lymphoma: Open Targets association 0.51 with non-Hodgkin lymphoma (MONDO_0018908); Skin cancer: Open Targets association 0.50 with skin cancer (MONDO_0002898); Acute myeloid leukaemia: Open Targets association 0.79 with acute myeloid leukaemia (MONDO_0018874); CIViC evidence names this disease

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; IntOGen calls it an activating (Act) driver in 1 cohort; CIViC holds 4 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Myeloid Neoplasm.

## Sources

- HGNC HGNC:10783: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10783
- UniProt Q01130: https://www.uniprot.org/uniprotkb/Q01130/entry
- NCBI Gene 6427: https://www.ncbi.nlm.nih.gov/gene/6427
- Ensembl ENSG00000161547: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000161547

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/), [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)
- pathways: [RNA splicing](https://onco.cc/pathways/rna-splicing/)

---
JSON: https://onco.cc/api/v1/entities/srsf2.json